Form 8-K

Send us Feedback

PDL BioPharma (PDLI)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	DATA CENTRAL

	STOCK CHART

	SEC FILINGS

	BALANCE

	INCOME

	CASH FLOW

Annual Reports

Quarterly Reports

8-K

8-K (Apr 30, 2013)8-K (Apr 22, 2013)8-K (Mar 21, 2013)8-K (Mar 12, 2013)8-K (Mar 11, 2013)8-K (Mar 6, 2013)8-K (Mar 4, 2013)8-K (Mar 1, 2013)8-K (Feb 27, 2013)8-K (Feb 15, 2013)8-K (Jan 30, 2013)8-K (Jan 29, 2013)8-K (Jan 7, 2013)8-K (Dec 17, 2012)8-K (Dec 11, 2012)8-K (Dec 6, 2012)8-K (Dec 5, 2012)8-K (Dec 3, 2012)8-K (Nov 13, 2012)8-K (Nov 5, 2012)8-K (Oct 9, 2012)8-K (Sep 14, 2012)8-K (Sep 11, 2012)8-K (Sep 6, 2012)8-K (Sep 5, 2012)8-K (Aug 2, 2012)8-K (Jul 13, 2012)8-K (Jul 12, 2012)8-K (Jun 19, 2012)8-K (Jun 15, 2012)8-K (Jun 14, 2012)8-K (Jun 13, 2012)8-K (Jun 6, 2012)8-K (Jun 5, 2012)8-K (May 14, 2012)8-K (May 3, 2012)8-K (Apr 27, 2012)8-K (Apr 20, 2012)8-K (Apr 12, 2012)8-K (Mar 14, 2012)8-K (Mar 13, 2012)8-K (Mar 8, 2012)8-K (Mar 6, 2012)8-K (Mar 5, 2012)8-K (Feb 28, 2012)8-K (Feb 23, 2012)8-K (Feb 17, 2012)8-K (Feb 13, 2012)8-K (Feb 2, 2012)8-K (Jan 24, 2012)8-K (Jan 20, 2012)8-K (Jan 9, 2012)8-K (Jan 6, 2012)8-K (Jan 4, 2012)8-K (Dec 19, 2011)8-K (Dec 16, 2011)8-K (Dec 15, 2011)8-K (Dec 12, 2011)8-K (Dec 7, 2011)8-K (Dec 5, 2011)8-K (Nov 15, 2011)8-K (Nov 9, 2011)8-K (Oct 19, 2011)8-K (Oct 4, 2011)8-K (Sep 27, 2011)8-K (Sep 20, 2011)8-K (Sep 15, 2011)8-K (Sep 8, 2011)8-K (Aug 16, 2011)8-K (Aug 12, 2011)8-K (Jul 27, 2011)8-K (Jul 11, 2011)8-K (Jul 5, 2011)8-K (Jun 27, 2011)8-K (Jun 24, 2011)8-K (Jun 16, 2011)8-K (Jun 9, 2011)8-K (Jun 6, 2011)8-K (Jun 1, 2011)8-K (May 27, 2011)8-K (May 26, 2011)8-K (May 24, 2011)8-K (May 16, 2011)8-K (May 13, 2011)8-K (May 11, 2011)8-K (Apr 27, 2011)8-K (Apr 18, 2011)8-K (Mar 22, 2011)8-K (Mar 8, 2011)8-K (Mar 7, 2011)8-K (Feb 28, 2011)8-K (Feb 16, 2011)8-K (Feb 8, 2011)8-K (Jan 26, 2011)8-K (Jan 25, 2011)8-K (Jan 24, 2011)8-K (Jan 18, 2011)8-K (Jan 10, 2011)8-K (Dec 20, 2010)8-K (Dec 10, 2010)8-K (Dec 1, 2010)8-K (Nov 16, 2010)8-K (Nov 10, 2010)8-K (Nov 5, 2010)8-K (Nov 2, 2010)8-K (Nov 1, 2010)8-K (Oct 27, 2010)8-K (Oct 7, 2010)8-K (Oct 4, 2010)8-K (Sep 21, 2010)8-K (Sep 16, 2010)8-K (Sep 13, 2010)8-K (Sep 10, 2010)8-K (Sep 9, 2010)8-K (Sep 1, 2010)8-K (Aug 24, 2010)8-K (Aug 20, 2010)8-K (Aug 13, 2010)8-K (Aug 12, 2010)8-K (Aug 5, 2010)8-K (Jul 28, 2010)8-K (Jul 12, 2010)8-K (Jul 1, 2010)8-K (Jun 16, 2010)8-K (Jun 10, 2010)8-K (May 13, 2010)8-K (May 12, 2010)8-K (Apr 29, 2010)8-K (Apr 19, 2010)8-K (Apr 8, 2010)8-K (Apr 5, 2010)8-K (Mar 26, 2010)8-K (Mar 15, 2010)8-K (Mar 9, 2010)8-K (Mar 2, 2010)8-K (Feb 8, 2010)8-K (Feb 2, 2010)8-K (Jan 29, 2010)8-K (Jan 22, 2010)8-K (Dec 22, 2009)8-K (Dec 16, 2009)8-K (Dec 3, 2009)8-K (Dec 2, 2009)8-K (Nov 25, 2009)8-K (Nov 24, 2009)8-K (Nov 18, 2009)8-K (Nov 13, 2009)8-K (Nov 6, 2009)8-K (Nov 3, 2009)8-K (Oct 28, 2009)8-K (Oct 21, 2009)8-K (Oct 5, 2009)8-K (Sep 18, 2009)8-K (Sep 15, 2009)8-K (Sep 8, 2009)8-K (Aug 10, 2009)8-K (Aug 6, 2009)8-K (Jul 31, 2009)8-K (Jun 10, 2009)8-K (May 11, 2009)8-K (Apr 28, 2009)8-K (Apr 1, 2009)8-K (Mar 17, 2009)8-K (Mar 3, 2009)8-K (Feb 18, 2009)8-K (Feb 5, 2009)8-K (Jan 5, 2009)8-K (Dec 24, 2008)8-K (Dec 23, 2008)8-K (Dec 22, 2008)8-K (Dec 19, 2008)8-K (Dec 16, 2008)8-K (Dec 8, 2008)8-K (Dec 5, 2008)8-K (Nov 20, 2008)8-K (Nov 12, 2008)8-K (Nov 10, 2008)8-K (Oct 10, 2008)8-K (Sep 25, 2008)8-K (Sep 22, 2008)8-K (Sep 19, 2008)8-K (Aug 28, 2008)8-K (Aug 19, 2008)8-K (Aug 14, 2008)8-K (Jul 17, 2008)8-K (Jun 26, 2008)8-K (Jun 23, 2008)8-K (Jun 12, 2008)8-K (May 29, 2008)8-K (May 14, 2008)8-K (Apr 10, 2008)8-K (Apr 1, 2008)8-K (Mar 19, 2008)8-K (Mar 13, 2008)8-K (Mar 11, 2008)8-K (Mar 5, 2008)8-K (Feb 21, 2008)8-K (Feb 4, 2008)8-K (Jan 3, 2008)8-K (Dec 21, 2007)8-K (Dec 17, 2007)8-K (Nov 14, 2007)8-K (Nov 7, 2007)8-K (Oct 30, 2007)8-K (Oct 17, 2007)8-K (Oct 3, 2007)8-K (Sep 13, 2007)8-K (Sep 4, 2007)8-K (Aug 21, 2007)8-K (Aug 6, 2007)8-K (Jul 31, 2007)8-K (Jun 22, 2007)8-K (May 17, 2007)8-K (May 15, 2007)8-K (May 8, 2007)8-K (May 2, 2007)8-K (Apr 18, 2007)8-K (Apr 12, 2007)8-K (Apr 9, 2007)8-K (Mar 22, 2007)8-K (Mar 19, 2007)8-K (Mar 14, 2007)8-K (Feb 28, 2007)8-K (Feb 21, 2007)8-K (Dec 19, 2006)8-K (Nov 21, 2006)8-K (Nov 8, 2006)8-K (Nov 6, 2006)8-K (Oct 23, 2006)8-K (Aug 30, 2006)8-K (Aug 29, 2006)8-K (Aug 9, 2006)8-K (Aug 3, 2006)8-K (Jul 26, 2006)8-K (Jul 6, 2006)8-K (Jun 20, 2006)8-K (Jun 6, 2006)8-K (May 24, 2006)8-K (May 15, 2006)8-K (May 8, 2006)8-K (May 5, 2006)8-K (May 2, 2006)8-K (Apr 24, 2006)8-K (Mar 20, 2006)8-K (Mar 17, 2006)8-K (Mar 10, 2006)8-K (Mar 3, 2006)8-K (Feb 27, 2006)8-K (Feb 7, 2006)8-K (Jan 10, 2006)8-K (Nov 4, 2005)8-K (Nov 3, 2005)8-K (Oct 5, 2005)8-K (Sep 19, 2005)8-K (Sep 13, 2005)8-K (Aug 10, 2005)8-K (Aug 8, 2005)8-K (Jul 19, 2005)8-K (Jun 14, 2005)8-K (Jun 2, 2005)8-K (May 4, 2005)8-K (Apr 22, 2005)8-K (Apr 20, 2005)8-K (Apr 4, 2005)8-K (Mar 25, 2005)8-K (Mar 17, 2005)8-K (Feb 25, 2005)8-K (Feb 16, 2005)8-K (Feb 9, 2005)8-K (Feb 7, 2005)8-K (Feb 4, 2005)8-K (Feb 1, 2005)8-K (Jan 27, 2005)8-K (Jan 14, 2005)8-K (Nov 1, 2004)8-K (Sep 17, 2004)8-K (Aug 10, 2004)8-K (May 6, 2004)8-K (Mar 17, 2004)8-K (Dec 24, 2003)8-K (Dec 2, 2003)8-K (Sep 30, 2003)8-K (Aug 15, 2003)8-K (Aug 14, 2003)8-K (Jul 29, 2003)8-K (Jul 9, 2003)8-K (Jul 8, 2003)8-K (Jul 7, 2003)8-K (Jun 23, 2003)8-K (Jun 17, 2003)8-K (Apr 29, 2003)8-K (Apr 18, 2003)8-K (Mar 21, 2002)8-K (Feb 14, 2001)8-K (Oct 6, 2000)8-K (Aug 29, 2000)8-K (Mar 1, 2000)8-K (Feb 14, 2000)

Other

PDL BioPharma 8-K 2010

Documents found in this filing:

Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 9, 2010

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756

(Commission File Number)

Delaware

94-3023969

(State or Other Jurisdiction

of Incorporation)

(I.R.S. Employer

Identification No.)

932 Southwood Boulevard

Incline Village, Nevada 89451

(Address of principal executive offices, with zip code)

(775) 832-8500

(Company’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On March 9, 2010, PDL BioPharma, Inc. (the “Company”) will make a presentation at the Cowen 30^th Annual Health Care Conference in Boston. A copy of the Company’s presentation materials has been posted to the Company’s website and is attached hereto as Exhibit 99.1.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, the information in this report, including the exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This Current Report will not be deemed an admission as to the materiality of any information in the report that is required to be disclosed solely by Regulation FD.

Cautionary Statements

This filing and the presentation include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company’s royalty assets or business are disclosed in the “Risk Factors” contained in the Company’s 2009 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2010. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.		Description

99.1		Presentation at the Cowen 30^th Annual Health Care Conference on March 9, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


PDL BIOPHARMA, INC. (Company)

By:		/s/ CHRISTINE LARSON
		Christine Larson
		Vice President and Chief Financial Officer

Dated: March 9, 2010

EXHIBIT INDEX


Exhibit No.		Description

99.1		Presentation at the Cowen 30^th Annual Health Care Conference on March 9, 2010

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.

Mobile | Advertise | Licensing & Partnerships | Blogger Tools | Jobs

PDL BioPharma (PDLI)

Annual Reports

Quarterly Reports

8-K

Other

Documents found in this filing: